Caribou Biosciences Q3 revenue declines, to discontinue lead clinical program

Overview

• US genome-editing biopharma's Q3 revenue fell yr/yr, net loss narrowed slightly

• Company to discontinue lead clinical programs and cut workforce amid restructuring

• On October 6, Caribou announced approval of restructuring operations, to explore alternatives, including merger, asset sale, or liquidation

Outlook

• Company is exploring strategic alternatives, including merger, acquisition, or possible dissolution

• Company plans to discontinue clinical trials and further development for vispa-cel and CB-011

• No timeline set for completion of strategic review; further updates only if action is approved

Result Drivers

• RESTRUCTURING AND COST CUTS - Co said it plans to discontinue clinical trials, reduce workforce, and implement other cost reduction measures as part of a restructuring amid a challenging financing environment for allogeneic CAR-T cell therapies

Company press release: ID:nGNX9bJjTR

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Caribou Biosciences, Inc. is $3.00, about 575.1% above its November 4 closing price of $0.44

Reuters Recommended Reads

• Nov 5 - Entrada Therapeutics Q3 net loss narrows as expenses fall

• Nov 5 - Fate Therapeutics Q3 net loss narrows as expenses fall

• Nov 5 - Cartesian Therapeutics Q3 net loss narrows

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)